Revance Therapeutics Inc. | Key People and Executives
L. Daniel Browne
President, Chief Executive Officer & Director
Angus C. Russell
Chairman
Julian S. Gangolli
Independent Director
Phyllis I. Gardner
Independent Director
Robert F. Byrnes
Independent Director
Philip J. Vickers
Independent Director
L. Daniel Browne
President, Chief Executive Officer & Director
Abhay Joshi
Chief Operating Officer
Cyril Allouche
Chief Financial & Accounting Officer
Conor Gallagher
Head-Medical Affairs & Aesthetics
Roman G. Rubio
Senior Vice President-Clinical Development
Samir M. Gharib
Vice President-Finance & Administration
Ben Putman
Vice President-Digital
Todd Erik Zavodnick
Chief Commercial Officer
Mukul Agarwal
Vice President-Business Development
Dustin Sjuts
Vice President-Strategy & Sales
Erica Bazerkanian
Vice President-Marketing
Jeanie D. Herbert
Director-Investor Relations & Communications
Justin Ford
Vice President-Human Resources & Head-People
Caryn G. McDowell
Secretary, Senior VP & General Counsel
Susanne Fors
Vice President-Regulatory Affairs
Sharon Broadston Hall
Vice President-Regulatory Affairs
Angus C. Russell
Chairman
Julian S. Gangolli
Independent Director
Phyllis I. Gardner
Independent Director
Robert F. Byrnes
Independent Director
Philip J. Vickers
Independent Director
| Address |
7555 Gateway Boulevard
Newark California 94560
United States
|
|
Employees
|
- |
| Website |
http://www.revance.com |
| Updated |
07/08/2019 |
| Revance Therapeutics, Inc. is a clinical stage biopharmaceutical company. It is engaged in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic, and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. |
